Literature DB >> 18423659

Allele and species dependent contractile defects by restrictive and hypertrophic cardiomyopathy-linked troponin I mutants.

Jennifer Davis1, Haitao Wen, Terri Edwards, Joseph M Metzger.   

Abstract

Restrictive cardiomyopathy (RCM) is a debilitating disease characterized by impaired ventricular filling, reduced ventricular volumes, and severe diastolic dysfunction. Hypertrophic cardiomyopathy (HCM) is characterized by ventricular hypertrophy and heightened risk of premature sudden cardiac death. These cardiomyopathies can result from mutations in the same gene that encodes for cardiac troponin I (cTnI). Acute genetic engineering of adult rat cardiac myocytes was used to ascertain whether primary physiologic outcomes could distinguish between RCM and HCM alleles at the cellular level. Co-transduction of cardiac myocytes with wild-type (WT) cTnI and RCM/HCM linked mutants in cTnI's inhibitory region (IR) demonstrated that WT cTnI preferentially incorporated into the sarcomere over IR mutants. The cTnI IR mutants exhibited minor effects in single myocyte Ca(2+)-activated tension assays yet prolonged relaxation and Ca(2+) decay. In comparison RCM cTnI mutants in the helix-4/C-terminal region demonstrated a) hyper-sensitivity to Ca(2+) under loaded conditions, b) slowed myocyte mechanical relaxation and Ca(2+) transient decay, c) frequency-dependent Ca(2+)-independent diastolic tone, d) heightened myofilament incorporation and e) irreversible cellular contractile defects with acute diltiazem administration. For species comparison, a subset of cTnI mutants were tested in isolated adult rabbit cardiac myocytes. Here, RCM and HCM mutant cTnIs exerted similar effects of slowed myocyte relaxation and Ca(2+) transient decay but did not show variable phenotypes by cTnI region. This study highlights cellular contractile defects by cardiomyopathy mutant cTnIs that are allele and species dependent. The species dependent results in particular raise important issues toward elucidating a unifying mechanistic pathway underlying the inherited cardiomyopathies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18423659      PMCID: PMC2443058          DOI: 10.1016/j.yjmcc.2008.02.274

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  43 in total

1.  Contemporary evaluation and management of hypertrophic cardiomyopathy.

Authors:  Eugene Braunwald; Christine E Seidman; Ulrich Sigwart
Journal:  Circulation       Date:  2002-09-10       Impact factor: 29.690

2.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model.

Authors:  Christopher Semsarian; Imran Ahmad; Michael Giewat; Dimitrios Georgakopoulos; Joachim P Schmitt; Bradley K McConnell; Steven Reiken; Ulrike Mende; Andrew R Marks; David A Kass; Christine E Seidman; J G Seidman
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 3.  Genetic engineering and therapy for inherited and acquired cardiomyopathies.

Authors:  Sharlene Day; Jennifer Davis; Margaret Westfall; Joseph Metzger
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

4.  Myofilament calcium sensitivity and cardiac disease: insights from troponin I isoforms and mutants.

Authors:  Margaret V Westfall; Andrea R Borton; Faris P Albayya; Joseph M Metzger
Journal:  Circ Res       Date:  2002-09-20       Impact factor: 17.367

5.  Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations.

Authors:  Jens Mogensen; Toru Kubo; Mauricio Duque; William Uribe; Anthony Shaw; Ross Murphy; Juan R Gimeno; Perry Elliott; William J McKenna
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

6.  Increased Ca2+ affinity of cardiac thin filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I.

Authors:  Tomoyoshi Kobayashi; R John Solaro
Journal:  J Biol Chem       Date:  2006-03-10       Impact factor: 5.157

7.  Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype.

Authors:  Toru Kubo; Juan R Gimeno; Ajay Bahl; Ulla Steffensen; Morten Steffensen; Eyman Osman; Rajesh Thaman; Jens Mogensen; Perry M Elliott; Yoshinori Doi; William J McKenna
Journal:  J Am Coll Cardiol       Date:  2007-06-11       Impact factor: 24.094

8.  Thin filament disinhibition by restrictive cardiomyopathy mutant R193H troponin I induces Ca2+-independent mechanical tone and acute myocyte remodeling.

Authors:  Jennifer Davis; Haitao Wen; Terri Edwards; Joseph M Metzger
Journal:  Circ Res       Date:  2007-04-26       Impact factor: 17.367

9.  Calcium-independent negative inotropy by beta-myosin heavy chain gene transfer in cardiac myocytes.

Authors:  Todd J Herron; Rene Vandenboom; Ekaterina Fomicheva; Lakshmi Mundada; Terri Edwards; Joseph M Metzger
Journal:  Circ Res       Date:  2007-03-15       Impact factor: 17.367

Review 10.  Molecular mechanisms of inherited cardiomyopathies.

Authors:  Diane Fatkin; Robert M Graham
Journal:  Physiol Rev       Date:  2002-10       Impact factor: 37.312

View more
  27 in total

1.  Diastolic dysfunction and thin filament dysregulation resulting from excitation-contraction uncoupling in a mouse model of restrictive cardiomyopathy.

Authors:  Jennifer Davis; Soichiro Yasuda; Nathan J Palpant; Joshua Martindale; Tamara Stevenson; Kimber Converso; Joseph M Metzger
Journal:  J Mol Cell Cardiol       Date:  2012-06-06       Impact factor: 5.000

2.  Molecular determinants of cardiac myocyte performance as conferred by isoform-specific TnI residues.

Authors:  Brian R Thompson; Evelyne M Houang; Yuk Y Sham; Joseph M Metzger
Journal:  Biophys J       Date:  2014-05-20       Impact factor: 4.033

Review 3.  Cell biology of sarcomeric protein engineering: disease modeling and therapeutic potential.

Authors:  Brian R Thompson; Joseph M Metzger
Journal:  Anat Rec (Hoboken)       Date:  2014-09       Impact factor: 2.064

4.  Pathogenic peptide deviations support a model of adaptive evolution of chordate cardiac performance by troponin mutations.

Authors:  Nathan J Palpant; Evelyne M Houang; Wayne Delport; Kenneth E M Hastings; Alexey V Onufriev; Yuk Y Sham; Joseph M Metzger
Journal:  Physiol Genomics       Date:  2010-04-27       Impact factor: 3.107

5.  Correcting diastolic dysfunction by Ca2+ desensitizing troponin in a transgenic mouse model of restrictive cardiomyopathy.

Authors:  Yuejin Li; Pierre-Yves Jean Charles; Changlong Nan; Jose Renato Pinto; Yingcai Wang; Jingsheng Liang; Gang Wu; Jie Tian; Han-Zhong Feng; James D Potter; J-P Jin; Xupei Huang
Journal:  J Mol Cell Cardiol       Date:  2010-05-15       Impact factor: 5.000

6.  Restrictive Cardiomyopathy Troponin I R145W Mutation Does Not Perturb Myofilament Length-dependent Activation in Human Cardiac Sarcomeres.

Authors:  Alexey V Dvornikov; Nikolai Smolin; Mengjie Zhang; Jody L Martin; Seth L Robia; Pieter P de Tombe
Journal:  J Biol Chem       Date:  2016-08-24       Impact factor: 5.157

7.  Sarcomere neutralization in inherited cardiomyopathy: small-molecule proof-of-concept to correct hyper-Ca2+-sensitive myofilaments.

Authors:  Brian R Thompson; Joshua Martindale; Joseph M Metzger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-13       Impact factor: 4.733

Review 8.  Cardiac troponin mutations and restrictive cardiomyopathy.

Authors:  Michelle S Parvatiyar; Jose Renato Pinto; David Dweck; James D Potter
Journal:  J Biomed Biotechnol       Date:  2010-06-08

9.  Combinatorial effects of double cardiomyopathy mutant alleles in rodent myocytes: a predictive cellular model of myofilament dysregulation in disease.

Authors:  Jennifer Davis; Joseph M Metzger
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

10.  Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.

Authors:  Adam S Helms; Frank M Davis; David Coleman; Sarah N Bartolone; Amelia A Glazier; Francis Pagani; Jaime M Yob; Sakthivel Sadayappan; Ellen Pedersen; Robert Lyons; Margaret V Westfall; Richard Jones; Mark W Russell; Sharlene M Day
Journal:  Circ Cardiovasc Genet       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.